• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Precision Optics Corporation Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    7/3/24 4:15:08 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $POCI alert in real time by email
    8-K
    false 0000867840 0000867840 2024-06-29 2024-06-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported) June 29, 2024

     

    PRECISION OPTICS CORPORATION, INC.

    (Exact name of registrant as specified in its charter)

     

    Massachusetts   001-10647   04-2795294
    (State or other jurisdiction   (Commission   (IRS Employer
    of incorporation)   File Number)   Identification No.)
             

     

    22 East Broadway
    Gardner
    , Massachusetts
      01440
    (Address of principal executive offices)   (Zip Code)

     

    (978) 630-1800

    (Registrant’s telephone number, including area code)

     

     

    N/A

     

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act: None

     

    Securities registered pursuant to Section 12(g) of the Act:

     

    Title of each class   Trading symbol(s)   Name of each exchange on which registered
    Common stock, par value $0.01 per share   POCI   The Nasdaq Stock Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

         

     

       
     

     

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    (b) and (e)

     

    On June 29, 2024, Jeffrey L. DiRubio, the Precision Optics Corporation, Inc.’s (the “Company”) Senior Vice President of Sales and Marketing, resigned from the Company effective as of June 30, 2024. In order to provide for a smooth transition and to make available to the Company his expertise with respect to the Company’s products and customers, the Company has entered into a Consulting Agreement for the one-year term beginning July 1, 2024 and ending June 30, 2025, during which the Company will pay Mr. DiRubio an aggregate amount of $110,000, payable in monthly installments over the one year term of the Consulting Agreement.

     

    In addition, the Company and Mr. DiRubio have modified his existing Employment Agreement with the Company to provide for, among other amendments, that (i) the term of Mr. DiRubio’s employment agreement ended June 30, 2024, (ii) his base salary was increased retroactively from December 1, 2023 through June 30, 2024, to be paid in a lump sum in the amount of $25,962, (iii) to set his bonus payment for the fiscal year ended June 30, 2024 in an amount equal to $44,000, (iv) to supersede the severance provisions in his Employment Agreement with the provisions of his Consulting Agreement, and (v) to amend his outstanding option agreements to allow for his vested options to be exercisable for one year after the end of his continuous services.

     

    Item 9.01 Financial Statements and Exhibits

     

    (d) Exhibits.

     

    Exhibit No. Description
    10.1Modification to Employment Agreement by and between Precision Optics Corporation, Inc. and Jeffrey L. DiRubio dated June 29, 2024.
    10.2Consulting Agreement by and between Precision Optics Corporation, Inc. and Jeffrey L. DiRubio dated June 29, 2024.
    104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

     

     2 

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      PRECISION OPTICS CORPORATION, INC.
       
       
       
    Date: July 3, 2024 By: /s/ Joseph N. Forkey
      Name: Joseph N. Forkey
    Title: President

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     3 

     

    Get the next $POCI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $POCI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $POCI
    SEC Filings

    View All

    Precision Optics Corporation Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

    8-K - PRECISION OPTICS CORPORATION, INC. (0000867840) (Filer)

    3/30/26 5:34:38 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 424B5 filed by Precision Optics Corporation Inc.

    424B5 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Filer)

    3/30/26 9:00:25 AM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 424B5 filed by Precision Optics Corporation Inc.

    424B5 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Filer)

    3/26/26 4:01:15 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $POCI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Precision Optics Corporation, Inc. Announces Pricing of Upsized $10 Million Public Offering of Common Stock

    GARDNER, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced the pricing of its previously announced underwritten public offering of 2,777,777 shares of its common stock at a public offering price of $3.60 per share, before deducting underwriting discounts and commissions and offering expenses. The oversubscribed offering was led by a mix of existing and new fundamental institutional investors and included participation from directors, officers and executive management of the company including Dr. Joseph N. Forkey, th

    3/27/26 7:30:00 AM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Precision Optics Corporation, Inc. Announces Proposed Public Offering of Common Stock

    GARDNER, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it is commencing an underwritten public offering of shares of its common stock (or common stock equivalents). The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Lucid Capital Markets is acting as the sole book-running manager for the offering. The offering is being made pursuant to a shelf registration statement on Form S-3 (

    3/26/26 4:01:00 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Precision Optics Reports Second Quarter Fiscal Year 2026 Financial Results

    GARDNER, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, announced operating results on an unaudited basis for its second quarter fiscal year 2026 for the period ended December 31, 2025. Q2 2026 Financial Highlights (3 Months Ended December 31, 2025): Revenue was $7.4 million, a quarterly record, compared to $4.5 million in the same quarter of the previous fiscal year, representing growth of approximately 63%, and compared to $6.7 million in the most recent sequential quarter.Production revenue was $6.4 million, a quarterly recor

    2/17/26 4:30:00 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $POCI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Needham Investment Management Llc

    3 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

    4/6/26 3:56:54 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Coll Wayne M

    4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

    4/2/26 4:15:18 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Traut Joseph

    4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

    4/1/26 4:15:03 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $POCI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Coll Wayne M bought $107,905,271 worth of shares (4,317 units at $24,995.43) (SEC Form 4)

    4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

    8/16/24 4:30:31 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Executive Officer Forkey Joseph Norman bought $17,228,869 worth of shares (1,725 units at $9,987.75), increasing direct ownership by 1% to 122,572 units (SEC Form 4)

    4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

    8/16/24 4:30:30 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Operating Officer Lawande Mahesh bought $17,248,850 worth of shares (1,726 units at $9,993.54) (SEC Form 4)

    4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

    8/16/24 4:30:33 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $POCI
    Leadership Updates

    Live Leadership Updates

    View All

    Precision Optics Appoints Joseph P. Pellegrino, Jr. to Board of Directors

    GARDNER, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, is pleased to announce the appointment of Joseph P. "JJ" Pellegrino, Jr. to its Board of Directors. Mr. Pellegrino, who will also serve as Chairman of the Board's Audit Committee, brings decades of operational and financial experience as well as an extensive knowledge of the medical device industry to the board. Mr. Pellegrino most recently served as Chief Financial Officer of LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of devices, implants and services for the treatm

    3/20/25 9:00:00 AM ET
    $LMAT
    $POCI
    Medical/Dental Instruments
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

    Precision Optics Appoints Buell Duncan to Board of Directors; Dr. Richard Miles Retires from Board

    GARDNER, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, is pleased to announce the appointment of Buell Duncan to its Board of Directors. Mr. Duncan brings decades of executive leadership and strategic expertise, further strengthening the Company's commitment to innovation and growth. With an extensive career in the technology and business sectors, Mr. Duncan held senior leadership positions at a number of IBM global business units from 1992 through 2020 where he was instrumental in driving marketing, strategy, and business deve

    3/4/25 4:30:00 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Precision Optics Appoints Clay Schwabe as VP of Sales and Marketing

    GARDNER, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, today announced the appointment of Clay Schwabe, as the Company's Vice President of Sales and Marketing. Mr. Schwabe has over fifteen years of experience in medical device market access, sales, sales management, global product marketing, and commercialization. He is an emerging technologies specialist with experience in early-stage commercialization of minimally invasive surgical products and procedures. Most recently, he served as VP Business Development, Commercial Strategy, CRO, an

    7/8/24 9:00:00 AM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $POCI
    Financials

    Live finance-specific insights

    View All

    Precision Optics Schedules Second Quarter of Fiscal Year 2026 Conference Call for February 17, 2026

    GARDNER, Mass., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it has scheduled a conference call to discuss the Company's second quarter fiscal year 2026 financial results on Tuesday, February 17, 2026, at 5:00 p.m. ET. The Company intends to release its financial results and to file its 10-Q after the close of the market on Tuesday, February 17, 2026, followed by the conference call. Conference Call Details Date and Time: Tuesday, February 17, 2026, at 5:00 p.m. ET. Call-in Information: Interest

    2/13/26 9:00:00 AM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Precision Optics Schedules First Quarter of Fiscal Year 2026 Conference Call for November 13, 2025

    GARDNER, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it has scheduled a conference call to discuss the Company's first quarter fiscal year 2026 financial results on Thursday, November 13, 2025, at 5:00 p.m. ET. The Company intends to release its financial results and to file its 10-Q after the close of the market on Thursday, November 13, 2025, followed by the conference call. Conference Call Details Date and Time: Thursday, November 13, 2025, at 5:00 p.m. ET. Call-in Information: Intere

    11/6/25 4:15:00 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Precision Optics Schedules Fourth Quarter and Fiscal Year 2025 Conference Call for September 29, 2025

    GARDNER, Mass., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it has scheduled a conference call to discuss the Company's fourth quarter and fiscal year 2025 financial results on Monday, September 29, 2025, at 5:00 p.m. ET. The Company intends to release its financial results and to file its 10-K after the close of the market on Monday, September 29, 2025, followed by the conference call. Conference Call Details Date and Time: Monday, September 29, 2025, at 5:00 p.m. ET. Call-in Information: Int

    9/24/25 4:15:00 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $POCI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Precision Optics Corporation Inc.

    SC 13G/A - PRECISION OPTICS CORPORATION, INC. (0000867840) (Subject)

    11/13/24 5:53:45 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Precision Optics Corporation Inc.

    SC 13G - PRECISION OPTICS CORPORATION, INC. (0000867840) (Subject)

    5/17/24 5:03:18 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care